This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2007.03.031v1 50/2/176    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ribichini, F. Articles by Virmani, R. Search for Related Content PubMed Articles by Ribichini, F. Articles by Virmani, R.

PRECLINICAL STUDY

Effects of Oral Prednisone After Stenting in a Rabbit Model of Established Atherosclerosis

Flavio Ribichini, MD^_*, Michael Joner, MD, Valeria Ferrero, MD^_*, Aloke V. Finn, MD, Johanna Crimins, BA, Gaku Nakazawa, MD, Eduardo Acampado, DVM, Frank D. Kolodgie, PhD, Corrado Vassanelli, MD^_* and Renu Virmani, MD^,_*

^_* Division of Cardiology of the Università di Verona, Ospedale Civile Maggiore, Verona, Italy
Cardiac Unit, Department of Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts
CVPath Institute, Inc., Gaithersburg, Maryland

Manuscript received November 27, 2006; revised manuscript received March 2, 2007, accepted March 6, 2007.

^_* Reprint requests and correspondence: Dr. Renu Virmani, Medical Director, CVPath, International Registry of Pathology, 19 Firstfield Road, Gaithersburg, Maryland 20878. (Email: rvirmani{at}cvpath.org).

Objectives: The aim of this study was to compare the effects of systemic prednisone in combination with a bare-metal stent (BMS) or a paclitaxel-eluting stent (Taxus, Boston Scientific Corp., Natick, Massachusetts) on neointimal inhibition and vessel healing in an atherosclerotic rabbit model.

Background: Inflammation plays a critical role in neointimal formation after coronary artery stenting. The efficacy of immunosuppressive doses of oral prednisone to inhibit in-stent neointimal proliferation was compared with BMS and with a commercially available paclitaxel-eluting stent (Taxus) in a rabbit model of established atherosclerosis.

Methods: Bilateral iliac artery injury in atherosclerotic New Zealand White rabbits fed an atherogenic diet was followed by stent implantation. Animals randomly received Taxus stents, BMS (Express, Boston Scientific Corp.) and placebo, or BMS and oral prednisone (2.1 mg/kg/day for the first 7 days, followed by 1.4 mg/kg/day for 14 days and 0.7 mg/kg/day for 21 days). Stented arterial segments were harvested at 42 days and processed for light microscopy, immunohistochemistry, and organoid culture.

Results: Compared with control subjects, prednisone-treated animals showed a 30% reduction in percent stenosis (p = 0.009), a 35% decrease in neointimal area (p < 0.003), and a 66% decrement in neointimal thickness (p < 0.001). Taxus stents also reduced all 3 parameters significantly (–34%, –39%, and –83%, respectively), but showed significantly more inflammatory cells and fibrin deposition and less endothelialization compared with the other 2 groups. Plaque burden was equal among groups, as shown by the identical stent and vessel area, and no remodeling was observed.

Conclusions: Systemic prednisone treatment and Taxus stents reduce neointimal formation compared with BMS. The extent of neointimal reduction is similar between prednisone- and Taxus stent-treated animals; however, Taxus stents resulted in a significantly greater delay in healing. Targeting of inflammatory pathways after percutaneous coronary intervention may be an efficacious way to prevent restenosis without the long-term risk of late thrombosis.

Abbreviations and Acronyms   BMS = bare-metal stent   BSA = bovine serum albumin   CRP = C-reactive protein   DES = drug-eluting stent   DMEM = Dulbecco’s modified Eagle’s medium   LSM = low-serum media

This article has been cited by other articles:

				A. V. Finn, M. John, G. Nakazawa, R. Polavarapu, V. Karmali, X. Xu, Q. Cheng, T. Davis, C. Raghunathan, E. Acampado, et al. Differential Healing After Sirolimus, Paclitaxel, and Bare Metal Stent Placement in Combination With Peroxisome Proliferator-Activator Receptor {gamma} Agonists: Requirement for mTOR/Akt2 in PPAR{gamma} Activation Circ. Res., November 6, 2009; 105(10): 1003 - 1012. [Abstract] [Full Text] [PDF]

				G. Niccoli, D. Schiavino, F. Belloni, G. Ferrante, G. La Torre, M. Conte, N. Cosentino, R. A. Montone, V. Sabato, F. Burzotta, et al. Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents Eur. Heart J., June 1, 2009; 30(11): 1340 - 1347. [Abstract] [Full Text] [PDF]

				M. Joner, K. Morimoto, H. Kasukawa, K. Steigerwald, S. Merl, G. Nakazawa, M. C. John, A. V. Finn, E. Acampado, F. D. Kolodgie, et al. Site-Specific Targeting of Nanoparticle Prednisolone Reduces In-Stent Restenosis in a Rabbit Model of Established Atheroma Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1960 - 1966. [Abstract] [Full Text] [PDF]

				S. Jimenez-Valero, R. Moreno, A. Sanchez-Recalde, G. Galeote, L. Calvo, A. Viana, E. Lopez de Sa, and J. Lopez-Sendon Review: Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era? Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 137 - 146. [Abstract] [PDF]